Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
Masakazu Toi, Frances Boyle, Young‐Hyuck Im, Mattea Reinisch, David Molthrop, Zefei Jiang, Ran Wei, Francisco Sapunar, Brenda R. Grimes, Sarah C. Nabinger, Stephen Johnston
Abstract
The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2- early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).
Topics & Concepts
AdjuvantMedicineOncologyCohortInternal medicineEndocrine systemAdjuvant therapyCancerHormoneAdvanced Breast Cancer TherapiesNeuroendocrine Tumor Research AdvancesLung Cancer Research Studies